Slim Weight Loss Clinic in Ann Arbor, MI
2035 Hogback Road · Ann Arbor, MI 48105
5.0(8 Google reviews)
Accepts insurance
Listing updated Oct 2, 2026
Rejuvaa Drips Med Spa
Rejuvaa Drips Med Spa · 2864 Carpenter Road · Ann Arbor, MI 48108
Listing updated October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
About this practice
The official website for Rejuvaa Drips Med Spa in Ann Arbor, MI did not load (ConnectionError: HTTPConnectionPool(host='rejuvaadrips.com', port=80): Max retries exceeded with url: / (Caused by NameResolutionError("<urllib3.connection.HTTPConnection object at 0x7fa4180fae00>: Failed to resolve 'rejuvaadrips.com' ([Errno -2] Name or service not known)"))), so this summary cannot be grounded in first-party page content. No medications, prices, or services are inferred from the directory dump.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Nearby providers in Ann Arbor
Facial Innovations By Shari
5245 Jackson Road · Ann Arbor, MI 48103
5.0(99 Google reviews · 7 in past year)
Accepts insurance
Listing updated Oct 2, 2026
Revived Body - Aesthetic & IV Therapy Services
2100 South Main Street · Ann Arbor, MI 48103
5.0(337 Google reviews · 51 in past year)
TelehealthAccepts insurance
Listing updated Oct 2, 2026
TelehealthAccepts insuranceSemaglutide todayTirzepatide today
Listing updated Oct 2, 2026
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs